Cristal Therapeutics specializes in its proprietary copper-free click chemistry platform, CliCr®, which is based on a unique 7-membered ring structure known as TMTHSI. This innovative technology offers several advantages over traditional copper-free click reagents, including faster reaction times, higher stability, and the ability to generate stable bioconjugates. The platform allows for a diverse range of click reactions due to the flexibility in attaching various linkers to the TMTHSI structure. This versatility enables the creation of complex biomolecular constructs, such as antibody-drug conjugates and targeted nanoparticles, which can be utilized in both therapeutic and diagnostic applications.

The CliCr® technology addresses common challenges faced in the life sciences, such as slow conversion rates and instability of reagents. By providing a highly reactive and water-soluble click reagent, Cristal Therapeutics enhances the efficiency of bioconjugation processes. The platform's capabilities extend to the synthesis of complex molecules and the efficient labeling of various biomolecules, making it a valuable tool for research and product development. Overall, Cristal Therapeutics aims to leverage its CliCr® technology through strategic partnerships to advance innovations in the fields of diagnostics and therapeutics.

Netherlands

Cristal Therapeutics focuses on its unique and proprietary copper free click chemistry CliCr®. CliCr® has a higher stability, enables faster reactions, and generates optimal bioconjugate products.
Our mission is to offer our CliCr® technology to partners under license agreements in different diagnostic and therapeutic areas.

Cristal Therapeutics

Company Details